Mimotopes

Executive Summary

Mimotopes is an Australian biotech company based in Melbourne that has developed a proprietary peptide-mimotope platform for discovering immunotherapeutics and diagnostics. By combining phage-display libraries with next-generation sequencing, the company identifies epitope-mimicking peptides that can be used as vaccines, antibody-generation tools, and biomarker assays. Its therapeutic focus includes oncology, immunology, and infectious disease, with the goal of creating off-the-shelf peptide vaccines that stimulate robust, targeted immune responses. Founded in 2020, Mimotopes has raised $150 million and is currently in Phase 1 clinical development, positioning itself as a leader in peptide-based immunotherapy. The company's platform addresses key limitations of traditional vaccine development, such as antigen discovery and manufacturing scalability. By leveraging its high-throughput screening capabilities, Mimotopes can rapidly identify peptide mimics that elicit specific immune responses, potentially reducing development timelines. The company's lead programs target solid tumors and infectious diseases, with initial clinical data expected in the near term. Given its strong funding base, experienced team, and innovative platform, Mimotopes is well-positioned to advance its pipeline and establish partnerships with larger pharmaceutical companies. However, as a Phase 1 company, execution risk remains high, and successful clinical validation will be critical for future value creation.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 clinical trial initiation for lead oncology peptide vaccine60% success
• Q4 2026Research collaboration with a top-20 pharma for infectious disease vaccine program30% success
• Q2 2026Publication of platform validation data in a peer-reviewed journal80% success